CEA, SCC and NSE levels in exhaled breath condensate - Possible markers for early detection of lung cancer

Journal of Breath Research

Volumn 7, Issue 4, 2013, Pages

  Zou, Yingchang ^a   Wang, Lin ^a   Zhao, Cong ^a   Hu, Yanjie ^b   Xu, Shan ^b   Ying, Kejing ^b   Wang, Ping ^a   Chen, Xing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; NEURON SPECIFIC ENOLASE; TUMOR MARKER; ENOLASE; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA RELATED ANTIGEN; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; EARLY DIAGNOSIS; EXHALATION; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PILOT STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SERUM; SQUAMOUS CELL CARCINOMA; BREATH ANALYSIS; LUNG TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED;

ANTIGENS, NEOPLASM; BREATH TESTS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; EARLY DIAGNOSIS; EXHALATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; ROC CURVE; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84889028599     PISSN: 17527155     EISSN: 17527163     Source Type: Journal    
DOI: 10.1088/1752-7155/7/4/047101     Document Type: Article

References (48)

1. Parkin D M et al 2005 Global cancer statistics, 2002 CA Cancer J. Clin. 55 74-108 (Pubitemid 40372904)
2. Siegel R, Naishadham D and Jemal A 2013 Cancer statistics, 2013 CA Cancer J. Clin. 63 11-30
3. Jantus-Lewintre E et al 2012 Update on biomarkers for the detection of lung cancer Lung Cancer: Targets Ther. 3 21-29
4. Blanchon T et al 2007 Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest x-ray (CXR) Lung Cancer 58 50-8 (Pubitemid 47385930)
5. Bach P B et al 2007 Screening for lung cancer: ACCP evidence-based clinical practice guidelines Chest 132 (2nd edn) 69S-77S
6. Dammas S, Patz E J and Goodman P C 2001 Identification of small lung nodules at autopsy: implications for lung cancer screening and overdiagnosis bias Lung Cancer 33 11-6 (Pubitemid 32586776)
7. Sung H J and Cho J Y 2008 Biomarkers for the lung cancer diagnosis and their advances in proteomics BMB Rep. 41 615-25
8. Barlesi F et al 2004 Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer Respir. Med. 98 357-62 (Pubitemid 38443696)
9. Kulpa J et al 2002 Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients Clin. Chem. 48 1931-7 (Pubitemid 35222751)
10. Molina R et al 2003 Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors Tumour Biol. 24 209-18 (Pubitemid 37500571)
11. Patz E J et al 2007 Panel of serum biomarkers for the diagnosis of lung cancer J. Clin. Oncol. 25 5578-83
12. Hunt J 2002 Exhaled breath condensate: an evolving tool for noninvasive evaluation of lung disease J. Allergy Clin. Immunol. 110 28-34 (Pubitemid 36132721)
13. Chan H P, Lewis C and Thomas P S 2009 Exhaled breath analysis: novel approach for early detection of lung cancer Lung Cancer 63 164-8
14. Dalaveris E et al 2009 VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer Lung Cancer 64 219-25
15. Carpagnano G E et al 2004 Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer Oncology 66 180-4 (Pubitemid 38813043)
16. Edge S B and Compton C C 2010 The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Ann. Surg. Oncol. 17 1471-4
17. Horvath I et al 2005 Exhaled breath condensate: methodological recommendations and unresolved questions Eur. Respir. J. 26 523-48 (Pubitemid 41264218)
18. Moro D et al 1995 CEA, CYFRA 21-1 and SCC in non-small cell lung cancer Lung Cancer 13 169-76
19. Kulpa J et al 2000 CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group Anticancer Res. 20 5035-40 (Pubitemid 32319075)
20. Molina R et al 2005 Pro-gastrin-releasing peptide (ProGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer Anticancer Res. 25 1773-8 (Pubitemid 40896801)
21. Jingjun D et al 2008 Clinical significance of measuring the CEA in exhaled breath condensate of patients with non-small cell lung cancer Clin. Pulm. Med. J. 13 828-30
22. Vassilakopoulos T et al 2001 Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer Lung Cancer 32 137-44 (Pubitemid 32372606)
23. Greenberg A K and Lee M S 2007 Biomarkers for lung cancer: clinical uses Curr. Opin. Pulm. Med. 13 249-55 (Pubitemid 46847287)
24. Shibayama T et al 2001 Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC) Lung Cancer 32 61-9 (Pubitemid 32224840)
25. Ariyoshi Y et al 1983 Evaluation of serum neuron-specific enolase as a tumor marker for carcinoma of the lung Gann 74 219-25 (Pubitemid 13066712)
26. Carney D N et al 1982 Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer Lancet 1 583-5 (Pubitemid 12171820)
27. Shibayama T et al 1992 Serum neuron specific enolase (NSE) levels in patients with non small cell lung cancer Nihon Kyobu Shikkan Gakkai Zasshi 30 1097-102
28. Mahmood S R et al 2011 Determination of neuron specific enolase (NSE) in small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) patients Pak. J. Pharmacol. 28 23-32
29. Nilsson O et al 1992 Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9 Br. J. Cancer 65 215-21
30. Staab H J et al 1978 Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer Am. J. Surg. 136 322-7 (Pubitemid 9017400)
31. Schlumberger M J et al 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer J. Clin. Oncol. 27 3794-801
32. Pacini F et al 1991 Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens Am. J. Clin. Pathol. 95 300-8
33. Steward A M et al 1974 Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress Cancer 33 1246-52
34. Safi F et al 1991 The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen Cancer 68 574-82
35. Moore T L et al 1971 Carcinoembryonic antigen assay in cancer of the colon and pancreas and other digestive tract disorders Am. J. Dig. Dis. 16 1-7
36. Campbell B and De'Ambrosis B 1990 Squamous cell carcinoma antigen in patients with cutaneous disorders J. Am. Acad. Dermatol. 22 639-42 (Pubitemid 20134706)
37. Torre G C 1998 SCC antigen in malignant and nonmalignant squamous lesions Tumour Biol. 19 517-26 (Pubitemid 28539335)
38. Cases A et al 1991 Tumor markers in chronic renal failure and hemodialysis patients Nephron 57 183-6
39. Johnson F L et al 2004 Improved diagnostic sensitivity for lung cancer using an automated quantitative cytology system and uridine 5′- triphosphate-induced sputum specimens Chest 125 157S-8S (Pubitemid 38648375)
40. Varella-Garcia M et al 2004 Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer Cancer Detect. Prev. 28 244-51 (Pubitemid 40125374)
41. London S J et al 2000 Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China Lancet 356 724-9 (Pubitemid 30663242)
42. Phillips M et al 2003 Detection of lung cancer with volatile markers in the breath Chest 123 2115-23 (Pubitemid 36706741)
43. Phillips M et al 2007 Prediction of lung cancer using volatile biomarkers in breath Cancer Biomark. 3 95-109 (Pubitemid 47103811)
44. Cornfield J et al 2009 Smoking and lung cancer: recent evidence and a discussion of some questions 1959 Int. J. Epidemiol. 38 1175-91
45. Taylor R, Najafi F and Dobson A 2007 Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent Int. J. Epidemiol. 36 1048-59 (Pubitemid 350019238)
46. Kashiwabara K, Nakamura H and Yokoi T 2001 Chronological change of serum carcinoembryonic antigen (CEA) concentrations and pulmonary function data after cessation of smoking in subjects with smoking-associated CEA abnormality Clin. Chim. Acta 303 25-32 (Pubitemid 32121802)
47. Zheng Y L et al 2012 Urinary bladder cancer risk factors in Egypt: a multicenter case-control study Cancer Epidemiol. Biomarkers Prev. 21 537-46
48. Bjerner J et al 2008 Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study Scand J. Clin. Lab. Invest. 68 703-13